The article focuses on the future of the biopharmaceutical sector in the U.S. The pharmaceutical industry is observed to be rising continuously as innovation on biosimilar products such as recombinant human growth hormone had been approved. The sales of these products are also returning a fair income with erythropoietin alone reached a $10.7-billion profit in 2005.